Document is current
Any future updates will be listed below
-
Authors
Andersen, Lærke Sloth https://orcid.org/0009-0001-6878-8602
Navarro, Ricardo Berenguer
Ekberg, Sara
Rögnvaldsson, Sæmundur https://orcid.org/0000-0003-2162-8414
Levy, Marína Rós
Sverrisdóttir, Ingigerður Sólveig
Viðarsson, Brynjar
Önundarson, Páll Torfi
Agnarsson, Bjarni A.
Sigurðardóttir, Margrét
Þorsteinsdóttir, Ingunn
Ólafsson, Ísleifur
Þórðardóttir, Ásdís Rósa
Eyþórsson, Elías
Jónsson, Ásbjörn
Ólafsson, Andri
Durie, Brian G. M.
Harding, Stephen
Landgren, Ola https://orcid.org/0000-0001-6485-4839
Löve, Thorvardur Jón
Kristinsson, Sigurður Yngvi
Thorsteinsdóttir, Sigrún https://orcid.org/0000-0001-5017-3530
-
Funding
Funding for this research was provided by:
Dr. Thorsteinsdottir has received research grants from Rigshospitalets Research Foundation and the European Hematology Association.
Dr Kristinsson has received research funding from the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research
- License Information
-
More Information
Article History
Received: 26 June 2025
Revised: 12 August 2025
Accepted: 2 September 2025
First Online: 12 September 2025
Competing interests
: LSA has participated in a conference supported by Alexion. SR: Honoraria for scientific talks from Johnson & Johnson and Siemens Healthineers. SH: Current employment at The Binding Site part of Thermo Fisher Scientific. OL: Research funding from NCI/NIH, FDA, LLS, Rising Tide Foundation, MMRF, IMF, Paula and Rodger Riney Foundation, Tow Foundation, Myeloma Solutions Fund, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; Independent Data Monitoring Committees for: Takeda, Merck, Janssen. SYK: Research funding from Amgen and Celgene; Independent Data Monitoring Committee for Jansen. ST: Honoraria for scientific talks/participated in advisory boards for Sanofi, Abbvie and the Binding Site, and travel grant from Amgen. ISS: Advisory board for Sanofi. The remaining authors declare no competing interests.
: The iStopMM study protocol was approved by the Icelandic National Bioethics Committee (Number 16-022, date: 2016-04-06) with approval from the Icelandic Data Protection Agency. Access to national healthcare registries has been approved by the Icelandic Directorate of Health and the Icelandic Cancer Society. Informed consent was obtained from all participants. All methods were performed in compliance with all relevant guidelines and regulations for use of Icelandic data.
